Omega Therapeutics, Inc.
Omega Therapeutics, Inc. (OMGA): 1 pipeline candidate · ~7 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
7.1 months
D/E 12.23 · 0% dilution
Lead: Phase 1/Phase 2
1 candidate
N/A
N/A
A transparent, data-derived signal for Omega Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$30.4M
Quarterly Burn
$14.0M
Runway
7.1 mo
Revenue
$2.6M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| otx-2002 | Phase 1/Phase 2 |
Frequently asked questions
How many drug candidates are in Omega Therapeutics, Inc.'s pipeline?
Omega Therapeutics, Inc. (OMGA) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Omega Therapeutics, Inc.'s lead drug candidate?
Omega Therapeutics, Inc.'s most advanced tracked candidate is otx-2002 (Phase 1/Phase 2) for Hepatocellular carcinoma (HCC).
What is Omega Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Omega Therapeutics, Inc. has approximately 7.1 months of cash runway.
Who is the CEO of Omega Therapeutics, Inc.?
Mahesh Karande is the chief executive officer of Omega Therapeutics, Inc. (OMGA).
Get the full picture on Omega Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.